Chongqing Genrix Biopharmaceutical Co., Ltd. Class ASSE: 688443

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Conditional Approval for Marketing of Velinotamig Injection

Aug 28, 2026 · Issued by Chongqing Genrix Biopharmaceutical Co., Ltd. Class A via Shanghai Stock Exchange

Announcement on Voluntary Disclosure of the Conditional Approval for Marketing of Velinotamig Injection

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

Company analysis

Earlier from Chongqing Genrix Biopharmaceutical Co., Ltd. Class A

"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of GR2302 Injection for the Indication of Chronic Hepatitis BAug 19
"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Obtaining the Notice of Approval for Clinical Trial of GR2302 InjectionAug 18
"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of the Acceptance of the New Drug Application for Telikibart Injection for the Treatment of Moderate-to-Severe Atopic Dermatitis in AdultsJul 17
"CHONGQING GENRIX BIOPHARMACEUTICAL CO., LTD."Announcement on Voluntary Disclosure of Withdrawal of Drug Registration ApplicationJul 1

All Chongqing Genrix Biopharmaceutical Co., Ltd. Class A news releases